A Phase II Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

  • STATUS
    Recruiting
  • End date
    May 25, 2023
  • participants needed
    250
  • sponsor
    Epizyme, Inc.
Updated on 25 January 2021
cancer
monoclonal antibodies
nitrosoureas
measurable disease
carcinoma
small molecule
growth factor
kidney function tests
cancer chemotherapy
solid tumour
beta human chorionic gonadotropin
ewing's sarcoma
renal function tests
synovial sarcoma
epithelioid sarcoma
extraskeletal myxoid chondrosarcoma
malignant peripheral nerve sheath tumor

Summary

This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID (twice daily) and 1600 mg QD (once daily). Subjects will be screened for eligibility within 21 days of the planned date of the first dose of tazemetostat and enrolled into one of 8 cohorts:

Cohort using tazemetostat 800 mg BID

  • Cohort 1 (Closed for enrollment): MRT, RTK, ATRT, and selected tumors with rhabdoid features, including small cell carcinoma of the ovary hypercalcemic type [SCCOHT], also known as malignant rhaboid tumor of the ovary [MRTO]
  • Cohort 2 (Closed for enrollment): Relapsed or refractory synovial sarcoma with SS18-SSX rearrangement
  • Cohort 3 (Closed for enrollment): Other INI1 negative tumors or any solid tumor with an EZH2 gain of function (GOF) mutation, including: epithelioid malignant peripheral nerve sheath tumor (EMPNST), extraskeletal myxoid chondrosarcoma (EMC), myoepithelial carcinoma, other INI1-negative malignant tumors with Sponsor approval (e.g., dedifferentiated chordoma) any solid tumor with an EZH2 GOF mutation including but not limited to Ewing's sarcoma and melanoma
  • Cohort 4 (Closed for enrollment): Renal medullary carcinoma (RMC)
  • Cohort 5 (Closed for enrollment): Epithelioid sarcoma (ES)
  • Cohort 6 (Opened for enrollment): Epithelioid sarcoma (ES) undergoing mandatory tumor biopsy
  • Cohort 7 (Opened for enrollment): Poorly differentiated chordoma (or other chordoma with Sponsor approval)

Cohort using tazemetostat 1600 mg QD

Cohort 8 (Opened for enrollment): Epitheliod sarcoma

Subjects will be dosed in continuous 28-day cycles. (Note: if treatment with study drug is discontinued prior to completing 2 years, subjects will be followed for a maximum duration of 2 years from start of study drug dosing.) Response assessment will be performed every 8 weeks while on study.

Treatment with tazemetostat will continue until disease progression, unacceptable toxicity or withdrawal of consent, or termination of the study.

Details
Condition Connective and Soft Tissue Neoplasm, Renal Cell Carcinoma, synovial sarcoma, Sarcoma, All Solid Tumors, Solid Tumors, Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), Selected Tumors With Rhabdoid Features, INI1-negative Tumors, Malignant Rhabdoid Tumor of Ovary, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Any Solid Tumor With an EZH2 GOF Mutation, Sarcoma (Pediatric), Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), INI1-negative Tumors, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), INI1-negative Tumors, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Renal Cell Cancer, Soft Tissue Sarcoma, Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), INI1-negative Tumors, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), INI1-negative Tumors, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), INI1-negative Tumors, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), INI1-negative Tumors, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), INI1-negative Tumors, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), INI1-negative Tumors, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), INI1-negative Tumors, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), INI1-negative Tumors, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), INI1-negative Tumors, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), INI1-negative Tumors, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), INI1-negative Tumors, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), epithelioid sarcoma, Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), INI1-negative Tumors, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval)
Treatment Tazemetostat
Clinical Study IdentifierNCT02601950
SponsorEpizyme, Inc.
Last Modified on25 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Atypical Teratoid Rhabdoid Tumors (ATRT) or Renal Cell Cancer or Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval) or Sarcoma o...?
Do you have any of these conditions: Sarcoma (Pediatric) or Malignant Rhabdoid Tumors (MRT) or Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval) or All Solid Tumors...?
Age (at the time of consent/assent): 18 years of age
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 NOTE: If subject is unable to walk due to paralysis, but is mobile in a wheelchair subject is considered to be ambulatory for the purpose of assessing their performance status
Has provided signed written informed consent
Has a life expectancy of >3 months
Has a malignancy
For which there are no standard therapies available (Cohorts 1, 3, 4 and 5)
That is relapsed or refractory after treatment with an approved therapy(ies), defined as metastatic or non-resectable, locally advanced disease that has previously been treated with and progressed following approved therapy(ies) (Cohort 2)
That has progressed within 6 months prior to study enrollment (Cohort 5 Expansion, Cohort 6 and Cohort 8 ONLY)
Has a documented local diagnostic pathology of original biopsy confirmed by a Clinical Laboratory Improvement Amendments (CLIA/College of American Pathologists (CAP) or equivalent laboratory certification
For Cohort 1 (rhabdoid tumors only), the following test results must be available by local laboratory: morphology and immunophenotypic panel consistent with rhabdoid tumors, and loss of INI1 or SMARCA4 confirmed by IHC, or molecular confirmation of tumor bi-allelic INI1 or SMARCA4 loss or mutation when INI1 or SMARCA4 IHC is equivocal or unavailable
For Cohort 2 (subjects with relapsed/refractory synovial sarcoma only), the following tests must be available by local laboratory: Morphology consistent with synovial sarcomas, and cytogenetics or fluorescence in situ hybridization (FISH) and/or molecular confirmation (e.g., DNA sequencing) of SS18 rearrangement t(X;18)(p11;q11)
For Cohort 3, 4, 5, 7 and 8 (subjects with INI1-negative/aberrant tumors or any solid tumor with EZH2 GOF mutation only), the following test results must be available by local laboratory: Morphology and immunophenotypic panel consistent with INI1-negative tumors (not applicable for solid tumors with EZH2 GOF mutation), and loss of INI1 confirmed by IHC, or molecular confirmation of tumor bi-allelic INI1 loss or mutation when INI1 IHC is equivocal or unavailable, or molecular evidence of EZH2 GOF mutation
For Cohort 6 (subjects with epithelioid sarcoma undergoing optional tumor biopsy)
Morphology and immunophenotypic panel consistent with epithelioid sarcoma (e.g., CD34, EMA, Keratin, and INI1)
If providing optional biopsy: Willingness to provide informed consent to undergo pre- and post-dose biopsy
Has all prior treatment (I.e. chemotherapy, immunotherapy, radiotherapy) related clinically significant toxicities resolve to Grade 1 per CTCAE version 4.0.3 or are clinically stable and not clinically significant, at time of enrollment
Prior anti-cancer therapy(ies), if applicable, must be completed according to the criteria below
Chemotherapy: cytotoxic (At least 14 days since last dose of chemotherapy prior to first dose of tazemetostat)
Chemotherapy: nitrosoureas (At least 6 weeks since last dose of nitrosoureas prior to first dose of tazemetostat)
Chemotherapy: non-cytotoxic (e.g., small molecule inhibitor) (At least 14 days since last dose of non-cytotoxic chemotherapy prior to first dose of tazemetostat)
Monoclonal antibody(ies) (At least 28 days since the last dose of any monoclonal antibody prior to first dose of tazemetostat)
Immunotherapy (e.g. tumor vaccine) (At least 42 days since last dose of immunotherapy agent(s) prior to first dose of tazemetostat)
Radiotherapy (RT) (At least 14 days from last local site RT prior to first dose of tazemetostat/At least 21 days from stereostatic radiosurgery prior to first dose of tazemetostat/At least 12 weeks from craniospinal, 50% radiation of pelvis, or total body irradiation prior to first dose of tazemetostat)
High dose therapy with autologous hematopoietic cell infusion (At least 60 days from last infusion prior to first dose of tazemetostat)
Hematopoietic growth factor (At least 14 days from last dose of hematopoietic growth factor prior to first dose of tazemetostat)
Has sufficient tumor tissue (slides or blocks) available for central confirmatory testing of IHC and/or cytogenetics/FISH and/or DNA mutation analysis (required for study entry but enrollment based on local results)
Has measurable disease based on either RECIST 1.1 for solid tumors or RANO for CNS tumors
Has adequate hematologic (bone marrow [BM] and coagulation factors), renal and hepatic function as defined by criteria below
Hematologic (BM Function)
Hemoglobin 9 mg/dL
Platelets 100,000/mm^3 (100x10^9/L)
ANC 1,000/mm^3 (1.0x10^9/L)
Hematologic (Coagulation Factors)
INR/PT <1.5 ULN
PTT>1.5 ULN
Renal Function
Serum creatinine 1.5 x ULN
Hepatic Function
Total bilirubin <1.5 x ULN(Eligibility can be determined by conjugated or total bilirubin)
AST and ALT <3 x ULN NOTE: Laboratory results obtained during screening should be used to determine eligibility criteria. In situations where laboratory results are outside the permitted range, the Investigator may retest the subject and the subsequent within range screening result may be used to determine the subject's eligibility
For subjects with CNS Tumors only, subject must have seizures that are stable, not increasing in frequency or severity and controlled on current anti-seizure medication(s) for a minimum of 21 days prior to the planned first dose of tazemetostat NOTE: Subjects may receive glucocorticoids (at stable or tapering dose) to control CNS symptoms prior to enrollment; however, subjects should receive a stable or tapering dose for at least 7 days prior to planned first dose of tazemetostat
Has a shortening fraction of >27% or an ejection fraction of 50% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan and New York Heart Association (NYHA) Class 2
Has a QT interval corrected by Fridericia's formula (QTcF) 480 msec
Female subjects of childbearing potential must
Have a negative beta-human chorionic gonadotropin (-hCG) pregnancy test at time of screening and within 14 days prior to planned first dose of tazemetostat (urine or serum test is acceptable however, positive urine tests must be confirmed with serum testing), and
Agree to use effective contraception, as defined in Section 8.6.1, from a minimum of 7 days prior to first dose until 6 months following the last dose of tazemetostat and have a male partner who uses a condom, or
Practice true abstinence (when this is in line with the preferred and usual lifestyle of the subject, see Section 8.6.1), or Have a male partner who is vasectomized
Male subjects with a female partner of childbearing potential must
Be vasectomized, or
Agree to use condoms as defined in Section 8.6.2, from first dose of tazemetostat until 3 months following the last dose of tazemetostat, or
Have a female partner who is NOT of childbearing potential

Exclusion Criteria

Has had prior exposure to tazemetostat or other inhibitor(s) of enhancer of zeste homologue-2 (EZH2)
Has participated in another interventional clinical study and received investigational drug within 30 days or 5 half-lives, whichever is longer, prior to the planned first dose of tazemetostat
Has known active CNS or any leptomeningeal metastasis of primary extra-cranial tumor. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging 4 weeks prior to the first dose of study drug and any neurologic symptoms have stabilized), have no evidence of new or enlarging brain metastases, and are on stable or tapering doses of steroids for at least 7 days prior to first dose of study drug. NOTE: Subjects with asymptomatic brain metastases found on screening MRI may be entered into the study without prior radiation therapy to the brain if they do not require immediate surgical or radiation therapy in the opinion of the treating investigator and in the opinion of a radiation therapy or neurosurgical consultant
Has had a prior malignancy other than the malignancies under study - EXCEPTION: A subject who has been disease-free for 5 years, or a subject with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma is eligible
Has had major surgery within 3 weeks prior to enrollment Note: Minor surgery (e.g., minor biopsy of extracranial site central venous catheter placement, shunt re-vision) is permitted 3 weeks prior to enrollment
Has Thrombocytopenia, neutropenia, or anemia of Grade 3 (per CTCAE 4.03 criteria) or any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS). Has abnormalities known to be associated with MDS (e.g. del 5q, chr 7 abn) and MPN (e.g. JAK2 V617F) observed in cytogenetic testing and DNA sequencing
NOTE: Bone marrow aspirate/biopsy will be conducted following abnormal
peripheral blood smear morphology assessment conducted by central laboratory
Cytogenetic testing and DNA sequencing will be conducted following an abnormal
result of bone marrow aspirate/biopsy
\. Has a prior history of T-LBL /T-ALL
\. Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit
from the diet and all foods that contain those fruits from time of enrollment
to while on study
\. Has cardiovascular impairment, history of congestive heart failure greater
than NYHA Class II, uncontrolled arterial hypertension, unstable angina
myocardial infarction, or stroke within 6 months prior to the planned first
dose of tazemetostat; or ventricular cardiac arrhythmia requiring medical
treatment
\. Is currently taking any prohibited medication(s)
\. Has an active infection requiring systemic treatment
\. Is immunocompromised (i.e. has congenital immunodeficiency), including
subjects known history of infection with human immunodeficiency virus (HIV)
\. Has known active infection with hepatitis B virus or hepatitis C virus
Note - Subjects with a history of hepatitis B or C with normal ALT and undetectable HBV DNA or HCV RNA are eligible for this study 14. Has had a symptomatic venous thrombosis within 2 weeks prior to study enrollment - NOTE: Subjects with a history of a deep vein thrombosis >2 weeks prior to study enrollment who are on anticoagulation therapy with low molecular weight heparin are eligible for this study 15. For subjects with CNS involvement (primary tumor or metastatic disease), have any active bleeding or new intratumoral hemorrhage of more than punctuate size of screening MRI obtained within 14 days of starting study drug or known bleeding diathesis or treatment with anti-platelet or anti-thrombotic agents 16. Has known hypersensitivity to any of the component of tazemetostat or other inhibitor(s)of EZH2 17. Is unable to take oral medications, or has a malabsorption syndrome or any uncontrolled gastrointestinal condition (e.g., nausea, diarrhea or vomiting) that would limit compliance with study requirements. 18. Has an uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, or psychiatric illness/social situations that would limit compliance with study requirements. 19. For female subjects of childbearing potential: Is pregnant or nursing 20. For male subjects: Is unwilling to adhere to contraception criteria from time of enrollment in the study to at least 3 months after last dose of tazemetostat
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note